SPAG9 controls the cell motility, invasion and angiogenesis of human osteosarcoma cells

Yang,Xiaorong; Zhou,Wenlai; Liu,Shiqing

doi:10.3892/etm.2015.2932

SPAG9 controls the cell motility, invasion and angiogenesis of human osteosarcoma cells

Authors:
- Xiaorong Yang
- Wenlai Zhou
- Shiqing Liu
View Affiliations

Affiliations: Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Joints, Central Hospital of Tujia and Miao Autonomous Prefecture, Enshi, Hubei 445000, P.R. China
Published online on: December 11, 2015 https://doi.org/10.3892/etm.2015.2932
Pages: 637-644

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sperm‑associated antigen 9 (SPAG9) is an oncoprotein involved in the progression of various human malignancies; however, its role in osteosarcoma (OS) remains poorly evaluated. The present study used Matrigel™ cell migration and invasion assays, tube formation assay, Cell Counting kit‑8, quantitative polymerase chain reaction, western blotting, and enzyme‑linked immunosorbent assay to investigate the role of SPAG9 in OS cell motility, invasion and angiogenesis. The results of the present study demonstrated that SPAG9 expression was upregulated in OS tissues, as compared with adjacent normal tissues, and knockdown of SPAG9 in an OS cell line inhibited cell motility and invasion via inactivation of metalloproteinase (MMP)‑2 and MMP‑9. Furthermore, the present study demonstrated that silencing of SPAG9 in OS cells inhibited tube formation, the proliferation of human umbilical vascular endothelial cells, and suppressed vascular endothelial growth factor (VEGF) expression and secretion, contributing to a reduction in angiogenesis. The results of the present study indicated that SPAG9 may be an important regulator in OS and may be involved in metastasis. Therefore SPAG9 may be a promising target for the treatment of metastatic OS.

View Figures

View References

1	Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age, State of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
2	Nau JY: New techniques in bone and joint imaging (2). Rev Med Suisse. 1:6512005.(In French). PubMed/NCBI
3	Klein MJ and Siegal GP: Osteosarcoma: Anatomic and histologic variants. Am J Clin Pathol. 125:555–581. 2006. View Article : Google Scholar : PubMed/NCBI
4	Hawkins DS and Arndt CA: Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer. 98:2447–2456. 2003. View Article : Google Scholar : PubMed/NCBI
5	Wu PK, Chen WM, Chen CF, Lee OK, Haung CK and Chen TH: Primary osteogenic sarcoma with pulmonary metastasis, Clinical results and prognostic factors in 91 patients. Jpn J Clin Oncol. 39:514–522. 2009. View Article : Google Scholar : PubMed/NCBI
6	Tan ML, Choong PF and Dass CR: Osteosarcoma. Conventional treatment vs. Histopathology. Cancer Biol Ther. 8:106–117. 2009. View Article : Google Scholar : PubMed/NCBI
7	Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
8	Zendman AJ, Ruiter DJ and Van Muijen GN: Cancer/testis-associated, genes. Identification, expression profile and putative function. J Cell Physiol. 194:272–288. 2003. View Article : Google Scholar : PubMed/NCBI
9	Jagadish N, Rana R, Selvi R, Mishra D, Garg M, Yadav S, Herr JC, Okumura K, Hasegawa A, Koyama K and Suri A: Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein. Biochem J. 389:73–82. 2005. View Article : Google Scholar : PubMed/NCBI
10	Jagadish N, Rana R, Mishra D, Kumar M and Suri A: Sperm associated antigen 9 (SPAG9): A new member of c-Jun NH2 -terminal kinase (JNK) interacting protein exclusively expressed in testis. Keio J Med. 54:66–71. 2005. View Article : Google Scholar : PubMed/NCBI
11	Garg M, Chaurasiya D, Rana R, Jagadish N, Kanojia D, Dudha N, Kamran N, Salhan S, Bhatnagar A, Suri S, et al: Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res. 13:1421–1428. 2007. View Article : Google Scholar : PubMed/NCBI
12	Garg M, Kanojia D, Khosla A, Dudha N, Sati S, Chaurasiya D, Jagadish N, Seth A, Kumar R, Gupta S, et al: Sperm-associated antigen 9 is associated with tumor growth, migration and invasion in renal cell carcinoma. Cancer Res. 68:8240–8248. 2008. View Article : Google Scholar : PubMed/NCBI
13	Sinha A, Agarwal S, Parashar D, Verma A, Saini S, Jagadish N, Ansari AS, Lohiya NK and Suri A: Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells, Possible implications in targeted therapy. J Exp Clin Cancer Res. 32:692013. View Article : Google Scholar : PubMed/NCBI
14	Volard B, Krieger S, Planchard G, Hardouin A, Vaur D, Rame JP and Bardet S: Assessment of SPAG9 transcript in fine needle aspirates of thyroid nodules. Eur Thyroid J. 1:118–121. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kanojia D, Garg M, Gupta S, Gupta A and Suri A: Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol. 178:1009–1020. 2011. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Dong Q, Miao Y, Fu L, Lin X and Wang E: Clinical significance and biological roles of SPAG9 overexpression in non-small cell lung cancer. Lung Cancer. 81:266–272. 2013. View Article : Google Scholar : PubMed/NCBI
17	Kanojia D, Garg M, Gupta S, Gupta A and Suri A: Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev. 18:630–639. 2009. View Article : Google Scholar : PubMed/NCBI
18	Garg M, Kanojia D, Suri S and Suri A: Small interfering RNA-mediated down-regulation of SPAG9 inhibits cervical tumor growth. Cancer. 115:5688–5699. 2009. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Burks DJ, Carballada R, Moore HD and Saling PM: Interaction of a tyrosine kinase from human sperm with the zona pellucida at fertilization. Science. 269:83–86. 1995. View Article : Google Scholar : PubMed/NCBI
21	Luconi M, Krausz C, Forti G and Baldi E: Extracellular calcium negatively modulates tyrosine phosphorylation and tyrosine kinase activity during capacitation of human spermatozoa. Biol Reprod. 55:207–216. 1996. View Article : Google Scholar : PubMed/NCBI
22	Garg M, Kanojia D, Salhan S, Suri S, Gupta A, Lohiya NK and Suri A: Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer. 115:2671–2683. 2009. View Article : Google Scholar : PubMed/NCBI
23	Hynes RO: Metastatic potential: Generic predisposition of the primary tumor or rare metastatic variants-or both? Cell. 113:821–823. 2003. View Article : Google Scholar : PubMed/NCBI
24	Halbersztadt A, Haloń A, Pajak J, Robaczynski J, Rabczynski J and St Gabryś M: The role of matrix metalloproteinases in tumor invasion and metastasis. Ginekol Pol. 77:63–71. 2006.(In Polish). PubMed/NCBI
25	Zhang XY, Hong BF, Chen GF, Lu YL and Zhong M: Significance of MMP2 and MMP9 expression in prostate cancer. Zhonghua Nan Ke Xue. 11:359–361. 2005.(In Chinese). PubMed/NCBI
26	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
27	Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 147:9–19. 1995.PubMed/NCBI
28	Czubayko F, Schulte AM, Berchem GJ and Wellstein A: Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci USA. 93:14753–14758. 1996. View Article : Google Scholar : PubMed/NCBI
29	Folkman J: Tumor angiogenesis: T herapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
30	Cao YEG, Wang E, Pal K, Dutta SK, Bar-Sagi D and Mukhopadhyay D: VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 72:3912–3918. 2012. View Article : Google Scholar : PubMed/NCBI
31	Xie K, Wei D, Shi Q and Huang S: Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 15:297–324. 2004. View Article : Google Scholar : PubMed/NCBI
32	Pal S, Datta K and Mukhopadhyay D: Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 61:6952–6957. 2001.PubMed/NCBI
33	Guma M, Rius J, Duong-Polk KX, Haddad GG, Lindsey JD and Karin M: Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc Natl Acad Sci USA. 106:8760–8765. 2009. View Article : Google Scholar : PubMed/NCBI